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Japanese encephalitis virus (JEV) induces human peripheral blood monocytes to secrete a chemotactic cytokine
[human macrophage-derived factor (hMDF)] which causes chemotaxis of neutrophils. The only known assay for
hMDF cannot quantify its level in samples, so an enzyme immunoassay has been standardized for detection of
hMDF and hMDF-specific antibodies in test samples. The reported enzyme linked im unosorbent assay (ELISA)
was found to be sensitive (89%), specific (91%), accurate (92·2%) and reproducible and was able to detect a minimum
concentration of 23 ng hMDF/ml in test samples. The chemotactic factor could be detected in JEV inoculated mouse
sera and JEV infected culture fluids. Significant finding of the test was the detection of hMDF in sera f human cases
of JE.
1. Introduction
Enzyme linked immunosorbent assay (ELISA) is a highly
sensitive technique which is specific, less time consuming
and reproducible method for detection and quantification of
many cytokines (Beech et al 1997; Jung et al 1998). Widely
used bioassays, which measure the ch motactic activity are
not easily applied to clinical samples because these assays
are not sensitive enough, time consuming and are easily
affected by other factors (Ida et al 1992). Human cytokine
measurements are now mostly performed with commercially
available or home made ELISA procedures (Ledur et al
1995).
  Japanese encephalitis virus (JEV, an arthropod-borne
flavivirus) infection remains one of the major causes of
encephalitis with significant mortality among children in
south-east Asia, including India. The most frequent altera-
tion during viral infections is leucocytopenia with lympho-
cytopenia (de Gruchy 1976); but JEV infection is associated
with leucocytosis and eutrophilia (Chaturvedi et al 1979).
An early influx of macrophages followed by n utrophils at
the site of injury in different human organs (Johnson et al
1985) and in experimental animals (Mathur et al 1988) has
been reported, yet the mechanism of recruitment of these
cells is undefined. We have shown that JEV induces spl nic
macrophages in mice and peripheral blood monocytes in
humans to secrete a highly potent chemotactic factor,
peptide of low molecular weight (~ 10 kDa), which causes
chemotaxis of neutrophils and is named macrophage
derived factor (MDF, Khanna et al 1991) and human
macrophage-derived factor (hMDF, Singh et al,
unpublished results) respectively. It is a biologically active
prote n (Mathur et al 1992; Khanna
et al 1993, 1994; Srivastava et al 1999). The in vivo studies
in mice have incriminated hMDF to play an important role in
pathogenesis of JEV infection (Singh
et al, unpublished results). It causes increase in capillary
permeability and break down of blood-brain barrier,
resulting in leakage of Evans blue dye bound protein into
peritoneal cavity and into brain substance. The only
method for detection of hMDF is the chemotactic activity
assay, by which the level cannot be quantified. Si ce hMDF
is a potent pathogenesis related protein, accurate
determination of it in the samples may be of great
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importance. Therefore, the present study was undertaken to
develop an ELISA for detection of hMDF and hMDF-
specific antibodies in clinical samples.
2.  Materials and methods
2.1  Animals and virus
The study was performed on 4–8 weeks old inbred con-
ventional Swiss albino mice, obtained from the mouse
colony maintained in the Department of Micr bio-
logy, KG Medical College, Lucknow. JEV strain 78668A
(Mathur et al 1982) was used in the form of infected adult
mouse brain suspension throughout the study.
2.2  Human peripheral blood cell culture
Human heparinized (10 U heparin/ml) venous blood was
obtained and allowed to stand at 37°C for 1 h for plasma to
separate. Buffy coat obtained from blood was applied to
Histopaque-1077 (Sigma Chemical Co., St. Louis, MO, USA)
and centrifuged at 500g for 30 min at room temperature
(Chaturvedi et al 1979). The mononuclear cell fraction was
collected, washed with Hank’s balanced
salt solution (HBSS), suspended in minimum essential
medium (MEM)–HEPES containing 5% foetal calf serum
(FCS) and antibiotics at a concentration of 5 × 106 cells/ml
and layered in glass Petri dishes for 1·5–2 h at 37°C in
humidified atmosphere of 5% CO2. More than 90% of the
adherent cells were macrophages as judged by morphology
and latex particles phagocytosis. The bottom layer
consisted of polymorphonuclear cells, which was collected
separately. More than 95% of these cells were neutrophils
on the morphology basis, which was studied in
Leishmann’s stained smears. The cells were washed and
suspended in HBSS. Cell viability was checked by Trypan
blue dye exclusion method.
2.3  Preparation of hMDF in vitro
The monocytes (5 × 106 viable cells/ml) in MEM–HEPES
with 5% FCS were stimulated with 102 LD50 of purified JEV
infected adult mouse brain suspension and cultured for 2 h
at 37°C in the presence of 5% CO2. The adherent cells were
washed thrice with phosphate buffered saline (PBS) and
incubated with normal saline (NS) for 24 h at 37°C in the
presence of CO2. The supernatant was collected,
centrifuged at 2000 g for 15 min and tested for neutrophil
chemotactic activity. The 24 h culture supernatant of
monocytes stimulated with normal mouse brain suspension
(10% w/v) was simultaneously prepared to serve as control.
  The crude supernatants from cultures of JEV-stimulated
human peripheral monocytes were concentrated by freeze
drying in Speed Vac (Savant Instruments Inc., New York).
The concentrated supernatant was purified on Superose-12
fast protein liquid chromatography (Pharmacia, Uppsala,
Sweden). The fractions obtained were tested for neutrophil
chemotactic activity. The protein content was estimated by
the technique of Lowry et al (1951). The chemotactic
fractions were concentrated before subjecting to SDS–
PAGE for molecular weight determination, in which hMDF
migrated as a single ~ 10 kDa band (Khanna et al 1991). It
reacted specifically with anti-hMDF antibodies in Western
blot and Dot-blot tests (Singh et al, unpublished results).
2.4  Assay of neutrophil chemotaxis
Neutrophil chemotaxis was assayed as described by
Khanna et al (1991). Briefly, purified human peripheral
neutrophils (1·5 × 106/200 ml) were taken in upper chamber of
multiwell chemotactic chamber (Millipore Inc., USA),
separated from the lower compartment by a 5 m pore size
nitrocellulose filter. The lower compartment was filled with
samples to be screened for chemotactic activity, which
included macrophage culture supernatants stimulated with
ither JEV or normal mouse brain suspen-
sion, while HBSS served as negative control. N-fo myl-
methionyl-leucyl-phenylalanine (FMLP, 10–7 M) was used
as a positive control. After incubation at 37°C in 5% CO2
atmosphere, the filters were removed, fixed in 70% isopropyl
alcoho  and stained with haematoxylin. The number of
neutrophils migrated into the filter was counted in 5–7
randomly selected high power fields (× 400). The samples
were tested in triplicate and mean ± SD was calculated.
2.5  Preparation of anti-hMDF antiserum
The anti-hMDF antiserum was prepared in 4–6 weeks old
inbred Swiss albino mice as described by Khanna et al
(1997). hMDF protein (100 mg) emulsified in Freund’s
complete adjuvant (Sigma) in 1 : 1 dilution was injected
intramuscularly (i.m.) on the inner side of the flanks and the
dose was repeated after 3 weeks, emulsified in 1 : 1 dilution
with Freund’s incomplete adjuvant (Sigma) intramuscul rly.
Following this, 3 intradermal (i.d.) injections
(60 mg hMDF protein/mouse) were given in the abdomin l
area at weekly intervals, without any adjuvant, at
4–5 places. This was followed by an intravenous (i.v.) injec-
tion (40 mg hMDF protein/mouse) 4 days before bleeding.
The mice were then bled by cardiac puncture, serum was
separated and inactivated at 56°C for 30 min. The optimal
dilution of antibody, which abrogated the chemotactic
activity of hMDF was determined and stored at – 70°C.
2.6  Study group
Eighty-two patients admitted with acute en ephalopathic
illness (acute, non-transient alteration of consciousness
with or without fever, or other neurological symptoms) in
Gandhi Memorial and Associated Hospitals, Lucknow were
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enrolled for the study. A proforma directed history was
taken and examination performed on admission. A careful
record of patient’s progress in hospital was maintained. JEV
infection was confirmed by either isolation and
identification of virus from cerebrospinal fluid (CSF) or its
detection i   CSF cells using indirect immunofluorescence
technique (Mathur et al 1990) or by measuring JEV specific
IgM antibody in acute CSF or 4-fold or greater rise in JEV
specific HAI antibody titre in the serum (Sharma et al 1991).
Acute phase serum was collected from all the patients on
admission to the hospital and convalescent phase sera after
an interval of 8–10 days. One or more indicators of JE
infection were present in 26 of the patients. Control group
consisted of serum samples from 20 normal healthy
individuals.
  Out of 26 JE confirmed patients included in the study, six
(23·08%) died within a week of admission, six (23%) patients
showed prolonged illness, while 14 (53·8%) recovered
completely.
2.7  ELISA
ELISA for hMDF was standardized by the modified method
of Voller et al (1976) for detection of hMDF and hMDF-
specific antibodies. The assay was carried out as follows:
  Flat-bottom microtitre plates (Nunc-Immuno Plate,
Denmark) were coated with different concentrations of
hMDF, ranging from 30 mg down to 23 ng and incubated in
humidified atmosphere in different conditions viz., at 4°C or
37°C for 1 h or overnight to optimize the conditions for
coating. The plates were washed and blocked for 1 h. After
washing, anti-hMDF antisera (hMDF-As) diluted 1/500 was
added to each well for 1 h at 37°C. For control, serum from
sham-immunized mice and PBS were used in place of hMDF-
As. Protein A conjugated with horse raddish peroxidase
(HRP), diluted 1/10,000 in PBST was used as conjugate and
O-phenylene-diamine as substrate. Sulphuric acid was
added to stop the reaction and absorbance was measured at
492 nm on a Titertek Multiscan Plus ELISA reader
(Labsystems, Finland). Absorbance values were either used
directly or the absorbance values of the standard sample
were used to construct a standard curve of arbitrary units. It
was observed that coating of plates at 37°C overnight
resulted in maximum absorbance development when
compared with those obtained at other temperatures.
  An inhibition ELISA for detection of hMDF in test
samples was also developed. The plate was coated over-
night at 4°C with hMDF-As (diluted 1 : 500 in PBS). After
washing and blocking as described above, test samples
were added and incubated at 37°C for 1 h. After washing,
protein A conjugated with HRP was added and the color
was developed as described above. Absorbance was
measured at 492 nm. Inhibition was calculated as follows:
Inhibition (%) = .100100
2
1
´
-
--
bB
bA
Where A is the absorbance of test sample, B is the
absorbance where only PBS is added in place of test
sample, b1 is the blank of the test sample and PBS where
anti hMDF-antisera not coated on the solid phase, and b2 is
the blank using PBS in u coated wells. All the serum
samples tested for hMDF in ELISA were confirmed by Dot-
blot and Western blot assay also (results not shown).
2.8  Statistical analysis
Every test was set up in triplicate and repeated 3 to 5 times.
The mean value ± SD from 9 to 15 values has been
presented. The indices of sensitivity, specificity and
accuracy of the established ELISA were calculated as
follows:
  Sensitivity = {(a/a + c) × 100}; specificity = {(d/b + c) ×
100} and accuracy = {(a + d)/(a + b + c + d)} × 100 where a
is the number of true positive samples, b is the number of
false positive samples, c i  the number of false negative
samples and d is the number of true negative samples
(Appassakij et al 1987). The samples positive in ELISA but
negative in Dot-blot and Western blot were considered
false positive; and samples negative in ELISA and positive
in Dot-blot and Western blot were considered false
negative.
3.  Results
3.1  Evaluation of detection limit of hMDF-
specific antibody
A checker board titration was done to find out the minimum
amount of hMDF that reacted with minimum amount of anti-
hMDF antibody by coating the plate with different
concentrations of hMDF ranging from 30 mg down to 6 ng.
The cut off value for optimum dilution of antibody was
calculated by adding 2 × SD with the mean bsorbance
obtained from the control. Macrophage culture supernatant
stimulated with normal mouse brain suspension was used
as hMDF control and serum from sham-immunized mice was
taken as anti-hMDF antibody control. It was observed that
in control (without hMDF), the cut off value was 0·128.
Minimum amount of hMDF that gave an bsorbance higher
than the cut off was taken as optimum. It was also found
that 1 : 500 dilution of hMDF-antibody gave an absorbance
of 0·167 which was above the cut off value and so was
taken a  optimum and with higher dilutions of antibody, the
absorbance was below the cut off value. The antibody
binding curve showed that a relatively low concentration of
hMDF was sufficient to coat the solid phase; so a
concentration of 375 ng hMDF was selected for further
development of the assay. Figure 1 shows the binding
curve of hMDF specific antibody with hMDF, projecting
50% of the maximum binding at 1: 500 dilution of anti-
Figure 1.  Titration of hMDF-specific antibodie . The plates were
coated with different concentrations of hMDF at 37°C overnight
and developed as described in §2.7. Macrophage culture
supernatant stimulated with normal mouse brain and serum from
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hMDF antibody. The absorbance values obtained were
used directly to estimate the amount of hMDF-specific
antibody in the test serum.
3.2  ELISA for detection of hMDF
An inhibition ELISA was developed for detection of hMDF
in test samples by coating anti-hMDF antibodies on the
solid phase as described in §2.7. Macrophage culture
supernatant stimulated with normal mouse brain suspensio
and serum from sham-immunized mice were includ d in the
assay as controls and per cent inhibition in absorbance
values of the test samples and the controls was calculated.
A standard curve presented in figure 2 was established by
assaying purified hMDF preparation. It
was observed that a concentration range of 3000 to 23 ng f
hMDF could be detected by the developed ELISA. The
curve was also used to detect hMDF quantitatively in test
samples. The sensitivity and reproducibility of the
established ELISA were estimated from this dose response
curve.
3.3  Comparison of sensitivity of ELISA with chemotactic
activity
A comparison of the sensitivity of ELISA test with neu-
trophil chemotaxis assay was made by titrating various
amounts of purified hMDF. Findings summarized in figure 3
demonstrate that with the neutrophil chemotactic activity
assay, the minimum amount of hMDF that could be
detected was about 500 ng; while hMDF ELISA
was significantly reactive up to a concentration of 23 ng
(figure 2). Various types of preparations were assayed to
test this system as follows.
3.4  Detection of hMDF in JEV-stimulated human
peripheral blood mononuclear cell subpopulations
Cultures of normal human peripheral blood cells or
its enriched subpopulations were stimulated with JEV
in vitro. Control cultures were simultaneously prepared by
stimulating the cells with normal mouse brain suspen-
sion. The culture supernatants were collected daily from 24
to 72 h and assayed for the presence of hMDF. An
inhibition ELISA was done to detect the presence of hMDF
in supernatants of JEV stimulated and control cultures.
Figure 4 shows a peak inhibition of 26 ± 4% at 24 h in
supernatants of total peripheral blood euc cyte cultures
and of 31 ± 5% in macrophage enriched culture super-
natants. The inhibition in supernatants from total cells as
well as in macrophage cultures decreased gradually in 48
and 72 h in comparison to that of 24h. T-cells and B-cells
enriched culture supernatants had no significant activity of
hMDF.
3.5  Detection of circulating hMDF in JEV-infected mice
Groups of mice were inoculated with 1000 LD50 of JEV
intracerebrally (i.c.). Blood was collected everyday from
Figure 2.  An inhibition ELISA for detection of chemotactic factor (hMDF) (
Plates were coated
overnight at 4°C with anti-hMDF antibodies (1 : 500 in PBS). Different
concentrations of hMDF were 
for 1 h at 37°C. Absorbance was measured at 492 nm and per cent inhibition was
calculated as described
in §2.7. Macrophage culture supernatant (MCS) stimulated with normal mouse
brain was included as hMDF con-
trol and serum from Sham-immunized mice as antibody control. The mean
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Figure 3.  Titration of chemotactic factor (hMDF) by neutrophil
chemotactic activity assay (¨) by modified Boyden chamber technique
a  described in §2.4, using different concentrations of hMDF. Each
s mple was tested in triplicate with neutrophil migration counted in 5–7
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these mice till 100% mortality was observed. The serum was
separated and screened for the presence of neutrophil
chemotactic activity by inhibition ELISA. Serum from mice
injected with normal mouse brain suspension was used as
control. Results presented in figure 5 show that significant
inhibition in hMDF-ELISA i.e., appearance of significant
amount of hMDF commenced from day 4 and peaked by
day 6 indicating maximum amount of circulating hMDF
when 100% mortality was observed.
3.6  Detection of hMDF in human sera
To detect the presence of hMDF in circulation, an inhibition
ELISA was performed in sera of 26 JE confirmed patients.
All 26 acute and 20 convalescent sera were screened for the
presence of hMDF. Twenty normal human sera were used
Figure 4.  An inhibition ELISA to detect the presence of chemotactic factor (hMDF) in culture
supernatants from in vitro JEV-stimulated human peripheral blood mononuclear cells (PBMC), or its
enriched subpopulation of macrophages, T-cells or B-cells. Controls were inoculated with normal mouse
brain (NMB) and uninoculated cult res were put up for blank. The test was repeated thrice and mean ± SD
was used to calculate per cent inhibition.
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Figure 5.  Inhibition ELISA for detection of chemotactic factor in sera of JEV-infected mice at different
days post infection. Sera from mice infected with normal mouse brain suspension (N) were used as control.
Blood, collected daily from both groups of mice was screened for the presence of chemotactic factor.
Mean absorbance from triplicate tests was used to calculate the per cent inhibition.
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as control. The cut off value for positivity of each test
serum was calculated by adding 2 × SD to the mean
inhibition value of the control sera. The results presented in
figure 6 show that 22 acute (84·6%) and 6 convalescent
(30%) sera from cases of JE had significant inhibition value
on hMDF-ELISA indicating the presence of hMDF like
protein in circulation. All 6 patients, who showed high level
of hMDF in second sample, were seriously ill at the time of
sample collection.
  The sensitivity, specificity and accuracy of the deve-
loped hMDF ELISA were also calculated. It was observed
that the described ELISA is reproducible and the specificity,
sensitivity and accuracy of the hMDF-inhibition ELISA
were found to be 91%, 89% and 92·2% respectiv ly.
4.  Discussion
In this study, the development of a sensitive ELISA method
for the determination of human monocyte-derived neutro-
phil chemotactic factor (hMDF) and its antibodies in the
test samples and demonstration of hMDF in sera of JE
confirmed patients is described. Cytokines play key roles in
a number of host defense reactions (Baggiolini 1998).
Among cells responding to chemokines, monocytes res-
pond to the widest among of mediators (M ntovani 1999).
Variations in the amount or quality of any chemokine or its
receptor would have bearable consequences for basal
trafficking of phagocytes. But now, they are also attracting
much attention as pathogenic or marker substance in
various diseases (Ida et al 1992). Accurate quantification of
such cytokines in body fluid samples is necessary
for further investigation of their relationship to various
diseases. This quantification is mostly performed by ELISA
(Ledur et al 1995), which has been described extensively
(Tsang and Weatherbee 1996; Beech t al 1997; Jung et al
1998). The only method for the detection of hMDF activity
ll now is the chemotactic assay using normal mouse
peritoneal neutrophils, by which the level of hMDF cannot
be quantified. Also, a minimum of about 500 ng/ml of hMDF
is required to give a positive reaction, while it was observed
in this study that with ELISA the minimum detection limit of
hMDF is up to 23 ng/ml, which is much lower than the other
known detection assay.
  Many proinflammatory c tokines including IL-8 have
been shown before neutrophil influx e.g., during bacterial
meningitis (Lopez-Cortes et al 1995) and aseptic meningitis
(Ishiguro et al 1997). The role of neutrophils in providing
first line of defense against bacterial (Benveniste 1992) and
viral (Srivastava et al 1999) infections has been
d monstrated. We have shown the production of hMDF
from human peripheral blood m nocytes in vitro upon
stimulation by JEV (Singh et al, unpublished results),
causing neutrophil chemotaxis. hMDF is a low molecular
weight (10 kDa), heat and pH resistant protein. In the
present study, it was again confirmed by inhibition ELISA.
The maximum activity of hMDF was observed at 24 h. JEV
stimulated B or T-cell enriched subpopulations failed to
produce any such chemotactic protein.
  Serum samples from 26 JE confirmed patients were
Figure 6.  Detection of hMDF antigen in circulation of JE confirmed patients by inhibition ELISA.
Twenty-six acute and twenty convalescent phase sera from JE confirmed patients were screened for
neutrophil chemotactic factor. Mean ± 2 SD from 20 normal human sera was taken as cut off value.
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collected and assayed for hMDF by ELISA. The study
revealed that hMDF and its antibodies could be easily
quantified in human samples by the described ELISA. The
reported ELISA is sensitive, simple and is directly appli-
cable to clinical specimens as compared to the other known
assay. MAC-ELISA positivity in the test group was found
to be 77% (20/26 CSF showed the presence of IgM
antibodies), while hMDF ELISA could detect anti-hMDF
antibodies in 84·6% of the acute serum. The reported
technique tells about the prognosis also and is preferred in
those cases where CSF is not available. In a number of
immune disorders (bacterial, fungal and viral infections) and
for inflammatory diseases (arthritis, non-septic shock etc.),
cytokine levels can be of great importance for diagnosis and
therapeutic treatments (Ledur et al 1995). The role of
chemokines in a wide range of inflammatory diseases and
host immune response makes them useful targets for
therapeutic intervention (Liles and Van Voorhis 1995; Gillis
and Williams 1998). Observations of neutralizing antibodies
in animal models of inflammation are promising (Adams and
Lloyd 1997). Sekido et al (1993) have shown that anti-IL-8
antibody is highly effective in a rabbit model of ischaemia
reperfusion injury in the lung.
  hMDF is a unique protein produced during JEV infection
only, therefore its use for rapid diagnosis is possible.
Because of the high sensitivity, the ELISA is expected to be
effectively used for further investigation on the involve-
ment of hMDF in pathogenecity during JEV infection.
Finally, complete information on the structure, pattern of
expression and functional roles of hMDF will clarify the full
potential of its use for therapeutic applications.
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